secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRAIL, Inc. (GRAL)
CIK:        0001699031
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001628280-24-043305
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRAIL appoints Sarah Krevans to Board of Directors, effective Oct 21
--------------------------------------------------------------------

- Krevans appointed as Class II director; will serve on Audit, Compensation, and Nominating & Governance Committees.
- Receives annual cash retainer of $50,000 plus committee retainers ($10k Audit, $7.5k Comp, $5k NCG), and initial grant of 31,055 RSUs vesting over 3 years.
- Krevans previously President and CEO of Sutter Health; Board now has 5 directors, 4 independent.
- Company disclosed ~$1.6M in 2023 payments to Sutter Institute for Medical Research for PATHFINDER 2 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699031/000162828024043305/0001628280-24-043305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699031/000162828024043305/gral-20241021.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-043305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer